Predictive Significance of Thymidylate Synthase Expression in Non-small Cell Lung Cancer

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11140%2F17%3A10366464" target="_blank" >RIV/00216208:11140/17:10366464 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00669806:_____/17:10366464

Výsledek na webu

<a href="http://dx.doi.org/10.21873/anticanres.12161" target="_blank" >http://dx.doi.org/10.21873/anticanres.12161</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.21873/anticanres.12161" target="_blank" >10.21873/anticanres.12161</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Predictive Significance of Thymidylate Synthase Expression in Non-small Cell Lung Cancer

Popis výsledku v původním jazyce

Background/Aim: To date, many studies have suggested that thymidylate synthase (TS) could be used as a prognostic and predictive marker in non-small cell lung cancer (NSCLC) patients. However, results have been contradictory. The aim of this study was to evaluate TS mRNA levels in tumor tissue of NSCLC patients who underwent complete surgical resection and to analyze its prognostic and predictive potential. Materials and Methods: The study group consisted of 64 patients who underwent curative lung resection. Paired lung tissue samples were taken directly from the tumor tissue and from adjacent, histologically cancer-free lung tissue. The quantitative estimation of TS expression was performed by reverse transcription real-time polymerase chain reaction (RT-qPCR). The relationship between TS expression level and disease-free interval (DFI) and overall survival (OS) was analyzed. Results: There was significantly higher TS expression in NSCLC tumor tissue comparing to normal lung tissue. In the group of patients who received adjuvant chemotherapy based on platinum derivatives in combination with paclitaxel or gemcitabine, we found shorter DFI (p= 0.0473) and OS (p= 0.0053) in those with high expression of TS. Conclusion: Our results demonstrated the relationship of high tumor tissue TS levels to adverse prognosis in patients undergoing adjuvant chemotherapy. TS is a non-specific tumor marker with respect to NSCLC, therefore we think that its best use would be as a member of the panel of predictors of adjuvant treatment efficacy.

Název v anglickém jazyce

Predictive Significance of Thymidylate Synthase Expression in Non-small Cell Lung Cancer

Popis výsledku anglicky

Background/Aim: To date, many studies have suggested that thymidylate synthase (TS) could be used as a prognostic and predictive marker in non-small cell lung cancer (NSCLC) patients. However, results have been contradictory. The aim of this study was to evaluate TS mRNA levels in tumor tissue of NSCLC patients who underwent complete surgical resection and to analyze its prognostic and predictive potential. Materials and Methods: The study group consisted of 64 patients who underwent curative lung resection. Paired lung tissue samples were taken directly from the tumor tissue and from adjacent, histologically cancer-free lung tissue. The quantitative estimation of TS expression was performed by reverse transcription real-time polymerase chain reaction (RT-qPCR). The relationship between TS expression level and disease-free interval (DFI) and overall survival (OS) was analyzed. Results: There was significantly higher TS expression in NSCLC tumor tissue comparing to normal lung tissue. In the group of patients who received adjuvant chemotherapy based on platinum derivatives in combination with paclitaxel or gemcitabine, we found shorter DFI (p= 0.0473) and OS (p= 0.0053) in those with high expression of TS. Conclusion: Our results demonstrated the relationship of high tumor tissue TS levels to adverse prognosis in patients undergoing adjuvant chemotherapy. TS is a non-specific tumor marker with respect to NSCLC, therefore we think that its best use would be as a member of the panel of predictors of adjuvant treatment efficacy.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30204 - Oncology

Projekt

—

Návaznosti

S - Specificky vyzkum na vysokych skolach

Rok uplatnění

2017

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Anticancer Research

ISSN

0250-7005

e-ISSN

—

Svazek periodika

37

Číslo periodika v rámci svazku

12

Stát vydavatele periodika

GR - Řecká republika

Počet stran výsledku

6

Strana od-do

6953-6958

Kód UT WoS článku

000417022100056

EID výsledku v databázi Scopus

2-s2.0-85038130110